Indaptus Therapeutics, Inc. (INDP) Stock

Indaptus Therapeutics, Inc., a pioneering clinical biotechnology company headquartered in New York, New York, specializes in the development of advanced immunotherapy products targeting cancer and viral infections. Formerly known as Intec Parent, Inc., the company rebranded to Indaptus Therapeutics, Inc. in August 2021, signaling its focus on innovative therapeutic solutions. Indaptus Therapeutics is dedicated to advancing treatments that harness the immune system's potential to combat a range of challenging diseases.

At the forefront of its pipeline is Decoy20, the company's lead clinical candidate currently undergoing Phase I clinical trials. Decoy20 aims to deliver single-agent activity and durable responses in lymphoma, hepatocellular carcinoma, colorectal cancer, pancreatic tumors, chronic hepatitis B virus, and human immunodeficiency virus infections. This innovative therapy underscores Indaptus Therapeutics' commitment to addressing critical unmet medical needs with transformative immunotherapies.

Founded on a robust scientific foundation, Indaptus Therapeutics combines cutting-edge research with strategic partnerships to drive therapeutic innovation. With a strong emphasis on precision medicine and immunological advancements, the company aims to redefine treatment paradigms and improve outcomes for patients globally.